CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ): Entry into a Material Definitive Agreement
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purcha
How this was made
The 30-second read
Why it matters
The acquisition secures a controlling stake in BioDefense, likely to be viewed as a strategic expansion by the market.
Market read
First‑report acquisition news for a micro‑cap biotech, likely to move CELZ shares on the day of filing.
What to watch
Funding source and dilution impact on existing shareholders.
Background
SEC Form 8‑K filed by Creative Medical Technology on Sep 25, 2026, detailing a material definitive agreement and unregistered equity sale.
Ticker impact
Creative Medical Technology filed an 8‑K reporting a Stock Purchase Agreement to acquire 80% of BioDefense for $200,000 cash and 1,000,000 CELZ shares.
Upward pressure on CELZ as investors price in the strategic stake.
First‑report 8‑K, material change in ownership; market typically reacts positively to control‑level acquisitions.
Market effects
Potential consolidation in the biotech/medical technology sector.
U.S. biotech market may see modest re‑rating of related peers.
Limited to niche biotech investors.
Counterpoint
The deal size is modest; integration risk could outweigh upside.
Key entities
- CompanyCreative Medical Technology Holdings, Inc.
Issuer of the 8‑K and acquirer.
- CompanyBioDefense, Inc.
Target company in which CELZ now holds 80%.
- CompanyCreative Acquisition Corp.
Seller of BioDefense shares.
